T2 comorbidities to be investigated in patients with severe asthma

Abstract

Since 2014, the Global Initiative for Asthma (GINA) has emphasized the importance of asthma control and personalized management of modifiable risk factors, including comorbidities. The variety of asthma-associated comorbidities can be grouped into three main categories: (1) type 2 inflammatory comorbidities, (2) potentially related to oral corticosteroid exposure, and (3) asthma-mimicking or aggravating asthma symptoms, observing some overlap between these groups. Evidence corroborates a high prevalence and the significant impact of type 2 inflammatory comorbidities in patients with severe asthma. This reality reinforces the need for an integral approach to asthma management, which includes systematic assessment and proper treatment of both asthma and associated conditions.